Latest news
Swedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3 - European Biotechnology MagazineEuropean Biotechnology Magazine · Mon, 10 Aug 2026 14:03:25 GMTM&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo - Pharmaceutical ExecutivePharmaceutical Executive · Mon, 10 Aug 2026 13:53:58 GMTSobi licenses lacutamab from Innate Pharma - The Pharma LetterThe Pharma Letter · Mon, 10 Aug 2026 13:46:07 GMTInnate Pharma S.A. and Swedish Orphan Biovitrum AB Enter Licensing Agreement for Lacutamab in T-Cell Lymphoma - marketscreener.commarketscreener.com · Mon, 10 Aug 2026 11:52:53 GMTSobi adds rare lymphoma drug with $580m Innate tie-up - pharmaphorumpharmaphorum · Mon, 10 Aug 2026 10:15:01 GMTInnate Pharma (NASDAQ: IPHA) secures Sobi deal, $75M upfront and Phase 3 push - Stock TitanStock Titan · Mon, 10 Aug 2026 10:05:10 GMTInnate Pharma advances lacutamab to Phase 3 and appoints CMO - World Business OutlookWorld Business Outlook · Mon, 10 Aug 2026 09:40:28 GMTAlmirall partners with CrystalO for dermatology drug discovery - World Business OutlookWorld Business Outlook · Mon, 10 Aug 2026 09:40:28 GMT